All News

Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients.

CURE spoke with Scott Paulson, M.D., medical oncologist with Texas Oncology, an affiliate of The US Oncology Network, to break down exactly what MSI-H status is, and the effects it may have on certain malignancies.

Who wears the face of cancer, and how can we spot them? In this thought-provoking article, one survivor shares her perspective.

Until recently, Herceptin, which is used to treat patients with metastatic breast cancer, was fully covered under Humana’s South Florida Medicare Advantage plans. But, after taking it off the preferred drug list, patients will now be responsible for 20 percent of the drug’s cost, better aligning South Florida’s plans with Humana’s other Medicare Advantage plans.

For many cancer survivors, returning to work can be both exciting and anxiety-inducing. Knowing your rights and making a plan can help ensure a smooth transition.

As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.

No matter how expensive treatment was, we didn’t want to put a price tag on my sister’s life.

With more than 200 cancer types identified, a male breast cancer survivor finds five to ponder.

The success of CAR- (chimeric antigen receptor) T cell therapy is causing landmark change in the way that patients with multiple myeloma are being treated, but more research needs to be done to better understand the role that these agents will play.

A change Felder hopes to evoke is to get more cervical cancer survivors talking about the disease to help eliminate the stigma attached to having a below the belt cancer.

The identification of microsatellite status, tumor mutational burden and protein expression in colorectal cancer (CRC) tumors may lead to better outcomes in a subgroup of patients.

Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.

When she was originally diagnosed, I knew nothing of palliative care. I had only heard about hospice, and the use of that word terrified me.

Lutathera (lutetium [177Lu] oxodotreotide) was approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) – a rare cancer that affects the pancreas and gastrointestinal tract.

Our lives are broken up after a loss, but eventually the pieces are put back together. The hard part is that the new pieces can make a totally different picture.

Patients previously treated for DNA mismatch repair (MMR)-deficient/microsatellite instability-high (MSI-H) metastatic colorectal cancer may have a new effective treatment option.

Throughout her life and especially in her fight against lung cancer, Mom set us an example in unconditional devotion, taught our family valuable life lessons and never lost her indomitable spirit.

Don't let the noise of other people's opinions distract you from making the right cancer treatment decision.

It's challenging to accept the physical limitations one may experience post-cancer, but changes to the body can pose real physical constraints.

Texas Rangers third-base coach Tony Beasley teams up with Fight CRC, sharing his journey into survivorship and inspiring others in their fight against cancer.

Even when a patient thinks they may have exhausted their very last treatment option, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study is just the thing they may need.

While only time will tell if the Cancer Moonshot will spearhead a decade of progress in five years, it is indisputable that Vice President Biden has brought the urgency to curing cancer back into focus.

I'm still scuffling with cancer, but that won't prevent other health conditions from creeping up.

Daniel J. George, M.D., discusses the role of immunotherapy, its continued integration into standards of care and what else the future holds for the treatment of bladder cancer.

Two-time cancer survivor encourages newly diagnosed patients to keep hope.

Man’s best friend has joined the fight against cancer by significantly helping families of children undergoing treatment.

A little focus on intentions for the week can help fight off cancer blues and allow more time for taking care of yourself.

Treatments and surgeries are a personal choice. Patients should talk with doctors and other patients and survivors to determine what is best for them.